Announcements
Projects
Orgs
Project
The Pharma Letter

Interested in joining The Pharma Letter?

Create your account and become part of this amazing organization. Start collaborating, sharing ideas, and building connections today!

Join The Pharma Letter Sign In First
Articles
15
First pill for dengue - JNJ-1802 - shows promise - The Pharma Letter
~2y
A decades-long program to develop the first new vaccine for pulmonary tuberculosis in a century has received a half-billion dollar funding boost. British drugmaker GSK (LSE: GSK) has been working on the jab, dubbed M72, since it picked up rights to the candidate through its 2005 purchase of American biotech Corixa. While the vaccine has shown 54% effectiveness in a Phase II trial enrolling around ... - The Pharma Letter
>2y
Initial safety and immunogenicity results from a Phase III trial of Bavarian Nordic's (OMX: BAVA) chikungunya virus vaccine candidate have been announced. The candidate is known as PXVX0317. The company said that the study has already met its primary efficacy endpoints, with a strong induction of chikungunya virus neutralizing antibodies having been observed in 87% of those receiving the ... - The Pharma Letter
>2y
Pfizer and GSK to battle for share of new RSV vaccine market - The Pharma Letter
>2y
The UK Department of Health and Social Care (DHSC) proposes £39 million ($48.5 million) of funding for antimicrobial resistance (AMR) research through the Global AMR Innovation Fund (GAMRIF). Of this new funding package, up to £24 million over four years has been awarded to bolster the UK's partnership with CARB-X – a global AMR research initiative – to support the continued early ... - The Pharma Letter
>2y
India's drug panel to review mRNA Omicron vaccine booster amidst COVID-19 surge - The Pharma Letter
>2y